Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Inclusion and Exclusion Criteria of Clinical Trials for Insomnia.

Huls H, Abdulahad S, Mackus M, van de Loo AJAE, Roehrs T, Roth T, Verster JC.

J Clin Med. 2018 Aug 8;7(8). pii: E206. doi: 10.3390/jcm7080206.

2.

Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.

Crossland DL, Denning WL, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Gold KS, Glisson BS, Cooper LJ, Heymach JV.

Oncogene. 2018 Jul;37(27):3686-3697. doi: 10.1038/s41388-018-0187-2. Epub 2018 Apr 6.

PMID:
29622795
3.

Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJ.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7788-E7797. Epub 2016 Nov 14.

4.

Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.

Najjar AM, Manuri PR, Olivares S, Flores L 2nd, Mi T, Huls H, Shpall EJ, Champlin RE, Turkman N, Paolillo V, Roszik J, Rabinovich B, Lee DA, Alauddin M, Gelovani J, Cooper LJ.

Mol Imaging Biol. 2016 Dec;18(6):838-848.

5.

Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.

Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ.

PLoS One. 2016 Aug 22;11(8):e0159477. doi: 10.1371/journal.pone.0159477. eCollection 2016.

6.

Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.

Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, Singh H, Huls H, Lee DA, Champlin RE, Heimberger AB, Cooper LJ.

J Immunother. 2016 Jun;39(5):205-17. doi: 10.1097/CJI.0000000000000126.

7.

Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application.

Torikai H, Mi T, Gragert L, Maiers M, Najjar A, Ang S, Maiti S, Dai J, Switzer KC, Huls H, Dulay GP, Reik A, Rebar EJ, Holmes MC, Gregory PD, Champlin RE, Shpall EJ, Cooper LJ.

Sci Rep. 2016 Feb 23;6:21757. doi: 10.1038/srep21757.

8.

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJ.

Cancer Res. 2015 Sep 1;75(17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139.

9.

Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma.

Krishnamurthy J, Rabinovich BA, Mi T, Switzer KC, Olivares S, Maiti SN, Plummer JB, Singh H, Kumaresan PR, Huls HM, Wang-Johanning F, Cooper LJ.

Clin Cancer Res. 2015 Jul 15;21(14):3241-51. doi: 10.1158/1078-0432.CCR-14-3197. Epub 2015 Mar 31.

10.

Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.

Liadi I, Singh H, Romain G, Rey-Villamizar N, Merouane A, Adolacion JR, Kebriaei P, Huls H, Qiu P, Roysam B, Cooper LJ, Varadarajan N.

Cancer Immunol Res. 2015 May;3(5):473-82. doi: 10.1158/2326-6066.CIR-14-0195. Epub 2015 Feb 24.

11.

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.

Forget MA, Malu S, Liu H, Toth C, Maiti S, Kale C, Haymaker C, Bernatchez C, Huls H, Wang E, Marincola FM, Hwu P, Cooper LJ, Radvanyi LG.

J Immunother. 2014 Nov-Dec;37(9):448-60. doi: 10.1097/CJI.0000000000000056.

12.

Tumor lysing genetically engineered T cells loaded with multi-modal imaging agents.

Bhatnagar P, Alauddin M, Bankson JA, Kirui D, Seifi P, Huls H, Lee DA, Babakhani A, Ferrari M, Li KC, Cooper LJ.

Sci Rep. 2014 Mar 28;4:4502. doi: 10.1038/srep04502.

13.

Driving CAR-based T-cell therapy to success.

Jena B, Moyes JS, Huls H, Cooper LJ.

Curr Hematol Malig Rep. 2014 Mar;9(1):50-6. doi: 10.1007/s11899-013-0197-7. Review.

14.

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Singh H, Huls H, Kebriaei P, Cooper LJ.

Immunol Rev. 2014 Jan;257(1):181-90. doi: 10.1111/imr.12137. Review.

15.

Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.

Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ.

PLoS One. 2013 May 31;8(5):e64138. doi: 10.1371/journal.pone.0064138. Print 2013.

16.

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.

Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJ.

Blood. 2013 Aug 22;122(8):1341-9. doi: 10.1182/blood-2013-03-478255. Epub 2013 Jun 5.

17.

Non-response in a pharmacy and patient-based intensive monitoring system: a quantitative study on non-response bias and reasons for non-response.

Härmark LV, Huls HJ, de Gier JJ, van Grootheest AC.

Int J Pharm Pract. 2014 Apr;22(2):159-62. doi: 10.1111/ijpp.12038. Epub 2013 May 20.

PMID:
23683068
18.

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.

Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ.

PLoS One. 2013;8(3):e57838. doi: 10.1371/journal.pone.0057838. Epub 2013 Mar 1.

19.

Sleeping beauty system to redirect T-cell specificity for human applications.

Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ.

J Immunother. 2013 Feb;36(2):112-23. doi: 10.1097/CJI.0b013e3182811ce9.

20.

Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ.

Mol Ther. 2013 Mar;21(3):638-47. doi: 10.1038/mt.2012.267. Epub 2013 Jan 8.

21.

Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64.

Bhatnagar P, Li Z, Choi Y, Guo J, Li F, Lee DY, Figliola M, Huls H, Lee DA, Zal T, Li KC, Cooper LJ.

Integr Biol (Camb). 2013 Jan;5(1):231-8. doi: 10.1039/c2ib20093g.

22.

A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy.

Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJ.

Clin Cancer Res. 2012 Sep 1;18(17):4733-42. doi: 10.1158/1078-0432.CCR-11-3234. Epub 2012 Jul 3.

23.

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovich B, Lee DA, Champlin RE, Bonini C, Naldini L, Rebar EJ, Gregory PD, Holmes MC, Cooper LJ.

Blood. 2012 Jun 14;119(24):5697-705. doi: 10.1182/blood-2012-01-405365. Epub 2012 Apr 24. Erratum in: Blood. 2015 Nov 26;126(22):2527. Rabinovitch, Brian [corrected to Rabinovich, Brian].

24.

Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.

O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJ.

Sci Rep. 2012;2:249. doi: 10.1038/srep00249. Epub 2012 Feb 13.

25.
26.

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.

Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ.

Hum Gene Ther. 2012 May;23(5):444-50. doi: 10.1089/hum.2011.167. Epub 2012 Jan 17.

27.

Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.

Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES.

Cancer Res. 2012 Jan 1;72(1):271-81. doi: 10.1158/0008-5472.CAN-11-2778. Epub 2011 Nov 10.

28.

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ.

Cancer Res. 2011 May 15;71(10):3516-27. doi: 10.1158/0008-5472.CAN-10-3843. Epub 2011 May 10. Erratum in: Cancer Res. 2011 Jul 1;71(13):4734.

29.

The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor.

Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mátés L, Izsvák Z, Ivics Z, Lee DA, Champlin RE, Cooper LJ.

Gene Ther. 2011 Sep;18(9):849-56. doi: 10.1038/gt.2011.40. Epub 2011 Mar 31.

30.

A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.

Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJ.

Biomed Microdevices. 2010 Oct;12(5):855-63. doi: 10.1007/s10544-010-9440-3.

31.

Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ.

Cancer Res. 2010 May 15;70(10):3915-24. doi: 10.1158/0008-5472.CAN-09-3845. Epub 2010 Apr 27.

32.

piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ.

Hum Gene Ther. 2010 Apr;21(4):427-37. doi: 10.1089/hum.2009.114.

33.

PET imaging of T cells derived from umbilical cord blood.

Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H, Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJ.

Leukemia. 2009 Mar;23(3):620-2. doi: 10.1038/leu.2008.256. Epub 2008 Oct 2. No abstract available.

34.

Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ.

Cancer Res. 2008 Apr 15;68(8):2961-71. doi: 10.1158/0008-5472.CAN-07-5600.

35.

Isolation and immortalization of lymphocytes.

Ling PD, Huls HM.

Curr Protoc Mol Biol. 2005 May;Chapter 28:Unit 28.2. doi: 10.1002/0471142727.mb2802s70.

PMID:
18265367
36.

Effects of peritoneal closure and suture material on adhesion formation in a rabbit model.

Whitfield RR, Stills HF Jr, Huls HR, Crouch JM, Hurd WW.

Am J Obstet Gynecol. 2007 Dec;197(6):644.e1-5.

PMID:
18060964
37.

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK.

Blood. 2006 Sep 15;108(6):1797-808. Epub 2006 Jun 1.

38.

Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation.

Amrolia PJ, Mucioli-Casadei G, Huls H, Heslop HE, Schindler J, Veys P, Vitetta ES, Brenner MK.

Cytotherapy. 2005;7(2):116-25. Review.

PMID:
16047416
39.

Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.

Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK.

Blood. 2003 Sep 15;102(6):2292-9. Epub 2003 May 22. Erratum in: Blood. 2004 Sep 15;104(6):1605.

40.

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.

Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM.

Recent Results Cancer Res. 2002;159:123-33.

PMID:
11785836
41.

T cell activation responses are differentially regulated during clinorotation and in spaceflight.

Hashemi BB, Penkala JE, Vens C, Huls H, Cubbage M, Sams CF.

FASEB J. 1999 Nov;13(14):2071-82.

PMID:
10544190
42.

Alterations in size, shape and osmotic behaviour of red cells after splenectomy: a study of their age dependence.

de Haan LD, Werre JM, Ruben AM, Huls HA, de Gier J, Staal GE.

Br J Haematol. 1988 May;69(1):71-80.

PMID:
3382600
43.

Phosphorylase activity in denervated skeletal muscle.

HULS HN, LEONARD SL.

Proc Soc Exp Biol Med. 1961 Oct;108:224-8. No abstract available.

PMID:
14449911
44.

Effect of chlorpromazine on levels of adenine nucleotides and creatine phosphate of brain.

WEINER N, HULS HN.

J Neurochem. 1961 Jul;7:180-5. No abstract available.

PMID:
13783910
45.

The content of adenine nucleotides and creatine phosphate in brain. II. Effect of chlorpromazine.

WEINER N, HULS HN.

Tech Doc Rep SAMTDR USAF Sch Aerosp Med. 1961 May;61-39:1-6. No abstract available.

PMID:
13783911

Supplemental Content

Support Center